A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

Conditions: Adjunctive Treatment of Major Depressive Disorder (MDD) Interventions: Drug: CLE-100; Drug: Placebo Sponsors: Clexio Biosciences Ltd. Recruiting

https://clinicaltrials.gov/study/NCT06340958

Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

More News: Depression | Research | Study